Company Overview of Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company develops exosome-based diagnostics technology platform that harvests comprehensive and dynamic molecular information contained within exosomes from various fresh or frozen biofluids to deliver personalized healthcare to guide treatment decisions and in real-time along the entire patient care continuum. It also develops MedOncAlyzer 170, a liquid biopsy pan-cancer panel that simultaneously interrogates exosomal RNA (exoRNA) and circulating tumor DNA (ctDNA) in a single assay, as well as identifies clinically actionable and functionally ...
266 Second Avenue
Waltham, MA 02451
Founded in 2008
Key Executives for Exosome Diagnostics, Inc.
Chief Executive Officer and President
Chief Science Officer and Founding Scientist
Head of Commercial Diagnostics
Compensation as of Fiscal Year 2017.
Exosome Diagnostics, Inc. Key Developments
Exosome Diagnostics, Inc. Continues to Expand Coverage Reach for its EPI Test
May 9 18
Exosome Diagnostics, Inc. has continued to make significant progress in expanding contracts to provide laboratory services and ExoDx® Prostate(IntelliScore) (EPI) testing through both public and private payers in the United States. Contracts executed in March and April 2018 have increased total covered lives from 82 million to 110 million plan members across the United States. This increase is based on a series of coverage decisions from regional private payers where are marketing the EPI test. This includes association member plans, independent community plans and state Medicaid programs. The company is advancing contracting decisions with a number of additional payers across the United States and expects to announce additional coverage determinations over the remainder of 2018.
Exosome Diagnostics Appoints Grannum Sant as Head of Medical Affairs
Mar 21 18
Exosome Diagnostics, Inc. announced the appointment of Dr. Grannum Sant as Head of Medical Affairs. In his more than two decades with Tufts University, Dr. Sant served as Professor and Chair of Urology at Tufts University School of Medicine, where he still holds an appointment as Professor of Urology. In addition to his impressive experience within clinical urology, Dr. Sant made an international name for himself as a pharma medical affairs and clinical development executive; serving as VP Medical Affairs for Oncology/Urology at Sanofi-Aventis US, VP and Head of Medical Affairs for Rare Diseases at Genzyme. Most recently, Dr. Sant was Medical Affairs Lead for OPKO Health Inc.
Exosome Diagnostics, Inc. Partners with Intezyne, Inc. to Develop Exosomal RNA-Based Assay for Novel Cancer Resistance Pathway Inhibitor
Mar 14 18
Exosome Diagnostics, Inc. announced a collaboration agreement with Intezyne, Inc. to design and validate a highly sensitive exosomal RNA based assay for use in Intezyne’s Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor for the treatment of pancreatic, gastric and other cancers in combination with existing anti-cancer therapies. The assay leverages Exosome Diagnostics’ ExoLution isolation kit, a cGMP-grade exosome RNA isolation platform, and is intended for the stratification and long-term monitoring of patients. Leveraging the company’s capabilities across both nucleic acid interrogation (cell free DNA + Exosomal RNA) and exosomal protein analysis, Exosome has already built a substantial portfolio of liquid biopsy and companion diagnostics.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 21, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries